40 results about "Tromethamine" patented technology

The invention belongs to the technical field of medicines, and particularly relates to a multi-effect composition containing ergothioneine, a preparation method of the multi-effect composition and application of the multi-effect composition in eye products. The multi-effect composition is prepared from ergothioneine, tromethamine and sodium hyaluronate according to the mass ratio of (0.5 to 10) to (1 to 5) to (0.5 to 3). According to the multi-effect composition containing the ergothioneine, the tromethamine in the composition can protect the stability of the ergothioneine under the conditions of illumination and high temperature; the ergosulfide can protect the activity of macromolecular sodium hyaluronate. The synergistic compatibility of the ergothioneine, the sodium hyaluronate and the tromethamine is utilized, so that the moisturizing effect and the eye protection effect of the composition can be remarkably improved. The ergothioneine-containing multi-effect composition provided by the invention has the effect of preventing cataract through specific components and proportions, and has the advantages of long-acting eye moistening and good stability.

To provide an ophthalmic product in which an ophthalmic composition is filled in a container in which a pressing deformation part is formed by using an elastic material, and although the ophthalmic composition contains chlorpheniramine, diphenhydramine or a salt thereof, adsorption of these components is suppressed.SOLUTION: An ophthalmic product comprising an ophthalmic composition and a container filled with the ophthalmic composition, wherein the container comprises a container body having a discharge port and a press-deforming part, and a cap, and the press-deforming part is formed using an elastic material, (A) one or more selected from the group consisting of chlorpheniramine, diphenhydramine, and pharmaceutically acceptable salts thereof, and (B) one or more selected from the group consisting of an amino acid and a salt thereof, glycyrrhizic acid and a salt thereof, a mucopolysaccharide and a salt thereof, trometamol and a salt thereof, ethylenediaminetetraacetic acid and a salt thereof, and a vitamin and a derivative thereof.SELECTED DRAWING: Figure 1

The invention relates to the technical field of pharmaceutical analysis, and particularly discloses a method for detecting related substances in lodoxamide tromethamine. According to the invention, chromatographic conditions are optimized, a C18 column with hybrid particles charged on the surface is used as a chromatographic column, gradient elution is carried out under a specific mobile phase, and a high performance liquid chromatography capable of effectively separating lodoxamide tromethamine from nine related substances is provided, and the related substances comprise INT1, INT2, LODT-A, LODT-B, LODT-C, LODT-D, LODT-E, LODT-F and LODT-G. Through methodological research and verification of specificity, sensitivity and the like, the detection method for the impurities in lodoxamide tromethamine provided by the invention is high in sensitivity and accuracy, and relatively good in reproducibility and durability, each impurity peak does not interfere with a main peak, each chromatographic peak can be well separated, and the detection method is suitable for large-scale industrial production. And a reliable guarantee is provided for better controlling the quality of the lodoxamide tromethamine product.

The present invention are co-crystals of Uric Acid with increased solubility with respect to crystals of Uric Acid, suitable for the pharmaceutical use. The invention comprises co-crystals with L-lysine, L-arginine, ethylene diamine, and tromethamine as co-formers, pharmaceutical compositions thereof and their therapeutical use in the prevention or treatment of cerebrovascular diseases.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

The invention relates to the technical field of tromethamine synthesis, in particular to a continuous flow synthesis process of tromethamine. Comprising the following steps: adding nitromethane and a solvent A into a container A to obtain a solution A; adding a depolymerizing agent, a solvent B and paraformaldehyde into a container B to obtain a solution B; the first feeding pump and the second feeding pump respectively convey the solution A and the solution B to a micro-channel reactor at the same time for condensation reaction to obtain condensation reaction liquid; transferring the condensation reaction solution to an acidification kettle, and adding a quenching solution for reaction to obtain a quenching reaction solution; diluting the quenching reaction solution, adding a decolorizing agent, and filtering to obtain a decolorizing reaction solution; adding the decolorization reaction liquid and a solvent C into a hydrogenation reaction system by using a circulating pump, and carrying out hydrogenation reaction under the action of hydrogen and a catalyst to obtain hydrogenation reaction liquid; concentrating the hydrogenation reaction liquid to remove the solvent to obtain a tromethamine crude product, and refining the tromethamine crude product to obtain a tromethamine finished product. The method has the effects of low safety risk, continuous and smooth continuous flow pipeline and high product yield and purity.

The present invention discloses a method for preparing ketorolac tromethamine impurity E. The method for preparing compound E comprises the following steps: subjecting compound I to an amino acid condensation reaction in the absence of a solvent to produce compound E; the amino acid condensation reaction is carried out at a temperature of 120°C to 180°C. The method utilizes a solvent-free reaction, is simple to operate, and avoids the production of ester byproducts. High-purity compound E is obtained in good yield and meets the requirements for use as an impurity reference substance (purity greater than 95%).

The present invention relates to a dengue vaccine formulation comprising a tetravalent dengue virus composition comprising a live attenuated dengue virus serotype 1, a live attenuated dengue virus serotype 2, a live attenuated dengue virus serotype 3, and a live attenuated dengue virus serotype 4, at least one non-reducing disaccharide, at least one poloxamer, urea, at least one amino acid having a positively charged side chain at neutral pH, tromethamine, and human serum albumin.

Salts of R-ketorolac, including solid salts, such as crystalline salts of the meglumine and tromethamine salts R-ketorolac, are disclosed. Methods of preparing such salts, pharmaceutical compositions comprising salts, and methods of treating cancer with such salts are further provided.

The application provides a low-deuterium water red ginseng and rhodiola compound mask as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The low-deuterium water red ginseng and rhodiola compound mask provided by the application comprises the following raw materials: a red ginseng and rhodiola compound, low-deuterium water, hydroxyethyl cellulose, carbomer-980, carbomer-981, panthenol, 1,2-hexanediol, p-hydroxyphenylacetone, glycerol, dipropylene glycol, beta-glucan, sodium alginate, disodium EDTA, betaine, allantoin, 1,3-butanediol, PEG-40 hydrogenated castor oil and tromethamine; the red ginseng and rhodiola compound is composed of red ginseng extract and rhodiola extract. The low-deuterium water red ginseng and rhodiola compound mask provided by the application has the effects of antioxidation, whitening and anti-photoaging, and can realize synergistic whitening and anti-photoaging.

The invention provides a bio-based efficient film-forming carrier for dissolving and stripping open and closed acnes, which is prepared from the following raw materials in percentage by weight: at least a phase A, a phase B and a phase C. The phase A at least comprises 0.1-1% of microcrystalline cellulose, 0.15-1% of cellulose gum, 3-8% of aureobasidium pullulans polysaccharide, 10-20% of alkaline blackhead exporting liquid, 2-5% of tromethamine and 30-80.25% of water; the phase B at least comprises 1-10% of caprylic / capric triglyceride and 0.5-5% of lauryl glucoside, and the phase C at least comprises 1-15% of cassava starch and 2-5% of 1, 2-pentanediol; the preparation method has the advantages that the reproducible bacterial nano cellulose is used as microcrystalline cellulose, so that a film forming system for dissolving and stripping open and closed acnes is milder and more effective, secondary injury to skin is avoided, and the film forming system is biodegradable, green and sustainable; the invention also provides a preparation method of the bio-based efficient film-forming carrier.

The invention discloses a tolvaptan sodium phosphate freeze-dried composition for injection and a preparation method of the tolvaptan sodium phosphate freeze-dried composition. The composition comprises tolvaptan sodium phosphate, tromethamine, disodium hydrogen phosphate and sodium dihydrogen phosphate, the molar ratio of the tolvaptan sodium phosphate to the tromethamine to the disodium hydrogen phosphate to the sodium dihydrogen phosphate is 1: (1.5-3.5): (2-4): (0.05-0.15). According to the invention, tromethamine is creatively adopted to replace cane sugar in the prior art to be used as a freeze-drying protective agent and a skeleton forming agent, so that the safety risks of high permeability, kidney burden, production pollution and the like possibly caused by the cane sugar are solved. In combination with a specific freeze-drying process comprising a pre-freeze-thawing step, the moisture content of the freeze-dried composition prepared by the invention can be lower than 0.3%, a stable freeze-dried cake-shaped structure is formed, and hydrolytic degradation of a main drug is effectively inhibited. Compared with the prior art, the composition provided by the invention has the beneficial effects of high safety, good stability and excellent product appearance.

The invention relates to the technical field of pharmaceutical preparations, in particular to a gadobutrol injection and a preparation method thereof. The gadobutrol injection comprises gadobutrol, sodium calcobutrol, arginine, a pH regulator and water for injection, the pH regulator is selected from one or more of citric acid, phosphoric acid, hydrochloric acid, acetic acid and tartaric acid, and the pH value of the injection is regulated to be about 6.6-8.0. The gadobutrol injection disclosed by the invention is good in stability, free gadolinium content meets requirements, tromethamine is prevented from being used, and liquid medicine is good in safety.

The invention provides transparent sunscreen gel and a preparation method thereof. The transparent sunscreen gel is prepared from the following raw materials in parts by weight: 10 to 20 parts of a sunscreen agent, 5 to 20 parts of a gelling agent, 0.01 to 0.15 part of a soft film forming agent, 0.5 to 5 parts of a neutralizing agent, 5 to 70 parts of water and 5 to 30 parts of an oil-phase solvent, wherein the neutralizer is composed of tromethamine and aminomethyl propanol, and the ratio of the tromethamine to the aminomethyl propanol is 1: (0.5-2); and the gelatinizing agent is an ionic gel HARMONIE SLEEKIONOC GEL, and the ionic gel is an ionic gel HARMONIE SLEEKIONOC GEL. The transparent sunscreen gel provided by the invention is not only good in sunscreen effect, but also good in stability and excellent in use experience, and the skin feels fresh and cool and is not sticky.

The invention relates to synthesis and application of a carboprost tromethamine chiral epoxy intermediate, and belongs to the technical field of chemical synthesis. The chiral epoxy intermediate compound as shown in the formula (I) is prepared from a compound as shown in the formula (II) and novel chiral sulfonium salt through catalytic asymmetric Corey-Chaykovsky reaction, reaction conditions are simple, and purification is easy. The invention also provides a method for preparing carboprost tromethamine from the compound as shown in the formula (I). The method is simple and convenient to operate, high in asymmetric selectivity and good in yield, the purification difficulty of the carboprost tromethamine is reduced, and the production cost is reduced.

The application discloses an arylpropionic acid non-steroidal anti-inflammatory drug preparation composition and a preparation method thereof. The composition is a solution preparation or a gel paste preparation containing arylpropionic acid non-steroidal anti-inflammatory drugs, and is characterized by containing arylpropionic acid non-steroidal anti-inflammatory drugs or isomers thereof and pharmaceutically acceptable solvents and adjuvants such as propylene glycol; wherein the mass / volume percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the solution preparation ranges from 1 mg / ml to 40 mg / ml, and the volume percentage of the propylene glycol ranges from 50% to 100%; the mass percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the gel paste preparation ranges from 1% to 10%, and the mass percentage of the propylene glycol ranges from 5% to 12%. The arylpropionic acid non-steroidal anti-inflammatory drugs in the prescription are in RS-configuration or derivatives, R-configuration or derivatives, S-configuration or derivatives, or a combination of the R-configuration or derivatives and the S-configuration or derivatives in any ratio; and the pH regulator is one or more of lysine, arginine, tromethamine, meglumine and the like.

The present invention relates to a dengue vaccine formulation comprising a tetravalent dengue virus composition comprising live attenuated dengue virus serotype 1, live attenuated dengue virus serotype 2, live attenuated dengue virus serotype 3, and live attenuated dengue virus serotype 4, at least one non-reducing disaccharide, at least one poloxamer, urea, at least one amino acid having a positively charged side chain at neutral pH, tromethamine, and human serum albumin.

The present invention relates to an aqueous ophthalmic composition comprising spirolactone, cyclodextrin and tromethamine, preferably for topical application to the human eye. The present inventors advantageously dissolve spirolactone in the HP-gamma cyclodextrin excipient at a concentration of 0.1%, which dose has been demonstrated to be effective in the treatment of ocular surface defects. They also have successfully demonstrated that the spirolactone eye drops are stable for up to 9 months at 4 DEG C and achieve its efficacy within at least 6 months, and the formulation is well tolerant after multiple daily instillations within 7 days. In addition, the spirolactone eye drops provided by the invention accelerate healing of corneal wounds of rats, reduce corneal edema and inflammation, enhance epithelial integrity and improve nerve regeneration, and prompt recovery of corneal homeostasis. Thus, the invention also relates to the use of an aqueous ophthalmic composition for the treatment of ocular diseases and disorders.

The present invention relates to a method for preparing crystals of tromethamine or hydrochloride thereof, and crystals of tromethamine or hydrochloride thereof prepared using the preparation method. By lowering the temperature and maintaining same at a constant temperature, large crystal particles of tromethamine or hydrochloride thereof can be obtained uniformly and with high purity.

The present invention relates to a stable aqueous formulation of Leucovorin calcium designed for parenteral administration. This formulation utilizes substituted cyclodextrins, specifically Betadex sulfobutyl ether cyclodextrin (SBE-β-CD) or Hydroxypropyl Beta Cyclodextrin (HP-β-CD), as solubilizers and stabilizers to enhance the drug's aqueous solubility. The inclusion of Tromethamine serves as a buffering agent, maintaining optimal pH levels and ensuring the chemical stability of Leucovorin over an extended shelf life. Importantly, the formulation effectively prevents drug crystallization and particulate matter formation, addressing major stability challenges associated with existing products. The formulation's resilience to freeze-thaw cycles confirm its physical and chemical stability under stress conditions. These advancements not only improve the safety and efficacy of Leucovorin calcium for intravenous administration but also facilitate compliance with regulatory standards, providing a reliable therapeutic option for patients.

The application provides an urapidil hydrochloride injection, and belongs to the field of chemical medicine preparation.The injection comprises urapidil hydrochloride, tromethamine and water for injection, and the pH value of the injection is 6.8-7.5.The application uses tromethamine to improve the pH value of the urapidil hydrochloride injection, greatly enhances the stability of urapidil hydrochloride, and still maintains the good solubility of urapidil hydrochloride at the higher pH value, the clarity of the injection is stable, the performance is excellent, and the product quality is obviously improved.

This invention provides a solid form of a compound, its preparation method, and its uses, belonging to the field of medicinal chemistry. The solid form includes a cocrystal of the compound with cinnamamide, or a cocrystal with p-toluenesulfonic acid; or a tromethamine salt of the compound. The solid form of the compound exhibits good stability and solubility.

This invention discloses an ophthalmic ketorolac tromethamine formulation and its preparation method. The ophthalmic ketorolac tromethamine formulation comprises the following components: ketorolac tromethamine, a gel matrix, an osmotic pressure regulator, and a diluent, wherein the gel matrix comprises low-acyl gellan gum and hydroxyethyl cellulose. In vitro release experiments show that the cumulative release rate of this invention reaches over 85% within 8 hours, and the release curve is flat. Compared with existing commercially available eye drops, it significantly reduces the frequency of administration and improves patient compliance. It maintains therapeutic efficacy while reducing the frequency of administration.

The invention provides a single-dose non-steroidal anti-inflammatory drug eye drop. According to the present invention, the compound represented by the formula I is obtained through splitting, and the research results show that the free acid of the compound represented by the formula I has characteristics of low water solubility, poor physical and chemical stability, easy moisture absorption, stickiness, poor fluidity and the like; therefore, various salt forms of the compound shown in the formula I are further researched, tromethamine salt of the compound shown in the formula I is finally selected as an effective component from multiple aspects of physicochemical properties and safety, and the eye drops are prepared through a preparation means to be directly used for eye drop administration, so that the problem that when a prodrug is directly used, the dosage of the tromethamine salt is reduced is effectively solved. And the loxoprofen active metabolite can be used for enriching the application of the loxoprofen active metabolite in antipyretic, analgesic and anti-inflammatory medicines.

The invention discloses a novel medicine for preventing and treating respiratory tract infection as well as a preparation method and application thereof. The effective components of the medicine comprise domiphen and tromethamine. Domiphen and tromethamine do not have a virus killing effect and especially kill new coronal viruses, but the pharmaceutical composition obtained by combining domiphen and tromethamine has a very strong sterilizing effect, also obtains a virus killing effect, can quickly kill viruses and bacterial pathogens within two minutes, can act on respiratory tracts, and has a good effect on killing new coronal viruses, so that the toxic and side effects of the respiratory tracts are reduced, and the toxic and side effects of the respiratory tracts are reduced. The compound has a unique treatment effect on respiratory diseases caused by bacterial and virus infection, and has a wide application prospect in preparation of novel drugs and disinfection products for preventing and treating respiratory infection.

This invention provides a dextro-ketoprofen tromethamine patch and its preparation method. The preparation method includes: S100, using raw materials including dextro-ketoprofen tromethamine, first polyacrylic acid, poly-N-isopropylacrylamide, chitosan, and titanium dioxide, preparing ketoprofen nanofibers by electrospinning; S200, using raw materials including ropivacaine, L-phenylalanine, second polyacrylic acid, and tetraethyl orthosilicate, preparing a matrix sol by a sol-gel method; S300, mixing the ketoprofen nanofibers and the matrix sol, and performing a gelation treatment to prepare the dextro-ketoprofen tromethamine patch. The dextro-ketoprofen tromethamine patch obtained by this invention has good photostability and a good sustained-release effect.

This invention relates to the pharmaceutical field, specifically disclosing the synthesis of a tromethamine linker and its application in drug coupling. The three-load linker uses tromethamine as the parent core, with three hydroxyl groups of tromethamine binding to three loads, and an amino group linked to maleimide, thus constructing a three-load linker. The linker proposed in this invention allows the three loads to be linked to three effector molecules through click chemistry, cyclization reactions, or disulfide bonds; the maleimide is then linked to a targeting ligand to construct a drug coupling agent with three load effector molecules.

Provided are tromethamine salts of 4-chloro-5-[4-(2, 6-dichlorophenyl) sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid, and forms thereof, as well as methods for preparing the tromethamine salts. Also provided are pharmaceutical compositions or veterinary compositions comprising the tromethamine salts and their use for the treatment of a number of diseases.

The invention provides a preparation method of bio-based tromethamine, which comprises the following steps: S1, taking bio-based 1, 3-dihydroxy acetone, hydrogen peroxide and an ammonia source as raw materials, and carrying out oxidation nitration reaction under the action of a catalyst to obtain 1, 3-dihydroxy nitropropane; and S2, adding a hydroxymethylation reagent into the 1, 3-dihydroxy nitropropane, carrying out condensation reaction under an alkaline condition, and carrying out hydrogenation reduction to obtain the bio-based tromethamine. According to the invention, a sustainable synthesis route based on bio-based raw materials is developed, renewable 1, 3-dihydroxy acetone which can be prepared through microbial fermentation is taken as a starting point, and the bio-based tromethamine is efficiently prepared through an optimized three-step method of oxidation nitration, condensation and reduction. According to the route, the reaction efficiency and selectivity are remarkably improved, the raw material cost and the process environment influence are effectively reduced, and a solid foundation is laid for green and economic production of bio-based tromethamine.

The invention discloses a pebiprofen ammonium salt as well as a crystal form, a preparation method and application thereof, relates to the technical field of medicinal chemistry, and provides the pebiprofen ammonium salt and the crystal form of the pebiprofen ammonium salt which are not disclosed in the prior art for the first time. Animal experiments show that compared with the pebiprofen free acid, the pebiprofen sodium salt and the pebiprofen tromethamine salt, the pebiprofen ammonium salt disclosed by the invention shows better pharmacokinetic characteristics, and an important basis is provided for developing a novel pebiprofen dosage form. In addition, the invention further provides a simple, convenient and efficient preparation process of the pebiprofen ammonium salt, the operability and repeatability are good, and an innovative technical path is provided for industrial production of high-added-value preparations.